-
The American study in BMJ Open compared more than 10,000 patients on tablets like temazepam with 23,000 similar patients not taking these drugs. Death risk among users was about four times higher, although the absolute risk was still relatively low.
BBC News (Medicina del Sonno) - Mar, 28 Febbraio 2012

http://news.bbc.co.uk
-
The U.S. Food and Drug Administration approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep. This is the first time the FDA has approved a drug for this condition. Intermezzo should only be used when a person has at least four hours of bedtime remaining. It should not be taken if alcohol has been consumed or with any other sleep aid.
Food and Drug Administration (Medicina del Sonno) - Lun, 28 Novembre 2011

http://www.fda.gov
-
New findings about brain rhythms could lead to the development of improved sleep treatments, a new study suggests. A team at Massachusetts General Hospital found that a brain rhythm regarded as the emblem of wakefulness persists in a hidden form during sleep, where it becomes more intense at certain times -- something that appears to affect people's vulnerability to being awakened by noise or other disturbances. To test their theory, the researchers used computerized electroencephalography (EEG) rhythms in 13 volunteers who slept -- or at least tried to -- three nights in the MGH Sleep Lab. At many intervals throughout each night, the volunteers were exposed to 10 seconds of typical background noises, such as traffic or a ringing telephone. The sounds were repeated at increasingly louder levels until the EEG showed that sleep had been disrupted. Analysis of the EEG measurements showed that the intensity of the alpha signal predicted how easily volunteers could be disturbed at the moment the measurement was taken, with a stronger alpha signal linked to more fragile sleep.
Medline Plus (Medicina del Sonno) - Lun, 7 Marzo 2011

http://www.nlm.nih.gov/medlineplus